|
I'm not sure that Dr. Carney will be ble to answer my questions, given the limited scope of the FDA guidelines. But...
In regards to early-stage patients,
1) Is this test currently in use for early-stage patients?
2) What studies have been done with this test and early-stage patients?
3) What are the treatment implications for an early-stage patient with a rising number? i.e., would the patient be put back on Herceptin while NED?
4) What are the limitations of the test-- how 'accurate' is it, how reliable is it?
If anyone on the site has info on the above, your input would be appreciated.
Many thanks,
Jen
|